Astute Analytica publishes a research report on the United States Liquid Biopsy Market. The analysis report contains in-depth data about demand, growth, opportunities, challenges, and restraints. In addition, it provides a thorough examination of the structure and possibility of global and regional industries.
United States Liquid Biopsy Market was valued at US$ 3,405.8 million in 2022 and is projected to surpass a market valuation of US$ 10,798 million by 2031 at a CAGR of 13.68% during the forecast period 2023–2031. It analyses the market’s regional trends, size, expansion prospects, and important factors in each region. Additionally, it acknowledges the impact of COVID-19, including updates on the Omicron mutation study, on the market. Both the direct and indirect effects of the pandemic on related industries are taken into account and discussed in the report.
The report gives a thorough analysis of the United States Liquid Biopsy Market, covering regional trends, market size, prospects for expansion, and important market factors in each region. In 2021, the United States Gross Domestic Product (GDP) value was US$ 23,315.08 billion, according to verified data from the World Bank. In terms of GDP, the United States accounts for 10.41% of the global economy. The mixed economy of the United States is very advanced. By nominal GDP, it has the largest economy in the world, and by purchasing power parity (PPP), it is second only to China in size.
The leading companies mentioned are
- Biocept, Inc.
- Illumina, Inc.
- Myriad Genetics, Inc.
- QIAGEN
- Thermo Fisher Scientific, Inc.
- Guardant Health
- F. Hoffmann-La Roche Ltd
- ANGLE plc
- BIODESIX
- NeoGenomics Laboratories, Inc.
- Other major players
The report also acknowledges the impact of COVID-19, including updates on the Omicron mutation study, on the market. It considers both the direct impact of the pandemic and the indirect influence on related industries. The observations on the pandemic’s impact are included in the report.
Furthermore, the report divides geographical regions into several major categories for production, consumption, revenue (in US dollars), and market share analysis. It discusses the predicted growth of the market in these regions between 2021 and 2031.
The segmentation overview of the United States Liquid Biopsy Market includes
By Technology
- Multi Gene Parallel Analysis (NGS)
- Single Gene Analysis (PCR Microarrays)
By Product
- Blood Sample Based
- Others
By Biomarker
- Circulating Nucleic Acids
- CTC
- Exosomes/Microvesicles
- Circulating Proteins